Sangamo Therapeutics, Inc. Common Stock
Compare this stock
SGMO Stock Report Card
$
31%
Performance
Score:
10/100
SGMO returned -87.01% in the last 12 months. Based on SPY's performance of 14.32%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
79/100
6 analysts offer 12-month price targets for SGMO. Together, they have an average target of 12, the most optimistic target put SGMO at 19 within 12-months and the most pessimistic has SGMO at 5.
Sentiment
Score:
65/100
SGMO had a bullish sentiment score of 64.58% across Twitter and StockTwits over the last 12 months. It had an average of 5.33 posts, 1.46 comments, and 3.79 likes per day.
Technicals
Score:
11/100
SGMO receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
10/100
SGMO has missed earnings 8 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, SGMO has had 2 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
35/100
SGMO has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.
Sangamo Therapeutics, Inc. Common Stock Summary
Nasdaq / SGMO
Healthcare
Biotechnology
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
SGMO scored poorly on our reportcard. Here are some similar companies and how they performed.
